Market Flux Event

Pfizer Pays $330M Upfront to License Three In Vivo CAR-T Programs From Starna Therapeutics

Read this in the Market Flux app

Pfizer has entered into an exclusive licensing agreement with Starna Therapeutics, a biotechnology company developing RNA medicines for in vivo therapeutics, to access three pre-IND in vivo chimeric antigen receptor T-cell programs targeting autoimmune diseases. Under the deal, Pfizer secures exclusive rights outside Greater China to develop, manufacture, and commercialize the programs, paying Starna $330 million upfront.

Starna is eligible for up to $2.30 billion in milestone payments on top of the upfront fee, plus royalties, bringing the total potential deal value to approximately $2.63 billion. Pfizer also holds options to expand its territorial rights to include Greater China, which would add further value to the agreement.

The deal underscores Pfizer's continued push into cell and gene therapy for autoimmune diseases, using in vivo CAR-T technology, which aims to engineer T-cells directly inside the patient rather than through the more complex ex vivo manufacturing process that has characterized earlier CAR-T approaches. All three programs are at the pre-IND stage, meaning they have not yet entered formal clinical development.

ยฉ AI-generated summary is provided by Market Flux

Sources

  1. InvestingForm 8K Accendra Health For: 18 November
  2. Newsfile_CorpTelo Genomics Announces Term Sheet Providing an Option for Exclusive Worldwide License to AI Technology for Automated Detection of Rare Malignant Cells Full Story: $TDSGF #TELO.CA #TELO.V #Chemicals #Biotechnology #OTC #OTCMarkets #OTCStocks #TSXV
  3. Business WirePfizer Enters into Exclusive Licensing Agreement with Starna Therapeutics for Autoimmune Diseases
  4. LiveSquawkPfizer: Enters Exclusive Licensing Agreement With Starna Therapeutics For Autoimmune Diseases - Obtains Exclusive Rights Outside Greater China For Three Pre-IND In Vivo CAR-T Programmes - Starna To Receive Upfront Payment Of $330M - Starna Eligible For Up To $2.30B In Milestone Payments Plus Royalties - Holds Options To Expand Territory To Include Greater China
  5. BioStocks$PFE Exclusive Licensing Agreement with Starna Therapeutics for Autoimmune Diseases Starna to receive an upfront payment of $330M
  6. Seeking AlphaPfizer, Starna ink cell therapy licensing deal worth up to $2.6B
  7. NasdaqPfizer Licenses Autoimmune Disease Programs From Starna In Deal Worth Upto $2.63 Bln
  8. MarketsdayPfizer Enters Exclusive Licensing Deal With Starna Therapeutics for Autoimmune CAR-T Programs, November 18, 2026 ๐Ÿ”น Pfizer $PFE has entered an exclusive licensing agreement with Starna Therapeutics for three pre-IND in vivo CAR-T programs focused on autoimmune diseases. ๐Ÿ”น Pfizer gains exclusive rights outside Greater China to develop, manufacture, and commercialize the programs. ๐Ÿ”น Starna will receive an upfront payment of $330 million. ๐Ÿ”น Starna is eligible for up to $2.3 billion in milestone payments tied to development and commercial achievements, plus royalties on net sales of approved products. ๐Ÿ”น Pfizer holds options to expand the territory to include Greater China. ๐Ÿ”น Pfizer will lead clinical development outside Greater China and plans to manufacture the initial clinical trial material at its U.S. facilities. ๐Ÿ”น Pfizer also gains rights to use Starna's in vivo CAR-T technology in inflammation, immunology, and oncology. #Pfizer #PFE #Starna #CAR_T #Biotech #Pharma